NCCN Clinical Practice Guidelines in Oncology (NCCN ...

1 Version , 05/20/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The nccn Guidelines and this illustration may not be reproduced in any form without the express written permission of nccn . nccn Guidelines Version and Treatment of Cancer-Related InfectionsNCCN Guidelines Index Table of Contents DiscussionNCCN Clinical Practice Guidelines in Oncology ( nccn Guidelines )Prevention and Treatment of Cancer-Related InfectionsVersion Guidelines Version and Treatment of Cancer-Related Infections nccn Guidelines Index Infections Table of Contents DiscussionVersion , 05/20/16 National Comprehensive Cancer Network, Inc.

2 2016, All rights reserved. The nccn Guidelines and this illustration may not be reproduced in any form without the express written permission of nccn .*Lindsey Robert Baden, MD Chair ФDana-Farber/Brigham and Women s Cancer Center | Massachusetts General Hospital Cancer CenterSankar Swaminathan, MD Vice-Chair ФHuntsman Cancer Institute at the University of UtahMichael Angarone, DO Ф Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityGayle Blouin, PharmD, BCOP Massachuetts General HospitalCancer CenterBernard C.

3 Camins, MD ФUniversity of Alabama at BirminghamComprehensive Cancer CenterCorey Casper, MD, MPH ФFred Hutchinson Cancer Research Center/Seattle Cancer Care AllianceBrenda Cooper, MD Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer InstituteContinueNCCN Guidelines Panel DisclosuresФ Infectious diseases Hematology/Hematology Oncology Internal medicineX Pulmonary medicine Medical Oncology Pharmacology* Discussion section writing committeeNCCN StaffKarin G. Hoffmann, RN, CCMC ourtney Smith, PhDErik R.

4 Dubberke, MD Ф Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of MedicineAshley Morris Engemann, PharmD, BCOP Duke Cancer InstituteAlison G. Freifeld, MD Ф Fred & Pamela Buffett Cancer Center John N. Greene, MD Ф Moffitt Cancer CenterJames I. Ito, MD Ф City of Hope ComprehensiveCancer CenterDaniel R. Kaul, MD ФUniversity of MichiganComprehensive Cancer CenterMark E. Lustberg, MD, PhD ФThe Ohio State University ComprehensiveCancer Center - James Cancer Hospitaland Solove Reseach InstituteJose G.

5 Montoya, MD ФStanford Cancer InstituteKen Rolston, MD Ф The University of Texas MD Anderson Cancer CenterGowri Satyanarayana, MD ФVanderbilt-Ingram Cancer CenterBrahm Segal, MD ФRoswell Park Cancer InstituteSusan K. Seo, MD Ф Memorial Sloan Kettering Cancer CenterShmuel Shoham, MD ФThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRandy Taplitz, MD ФUC San Diego Moores Cancer CenterJeffrey Topal, MD Yale Cancer Center/Smilow Cancer HospitalJohn W. Wilson, MD ФMayo Clinic Cancer Center **Printed by Brian Hill on 10/1/2016 3:49:18 PM.

6 For personal use only. Not approved for distribution. Copyright 2016 National Comprehensive Cancer Network, Inc., All Rights Guidelines Version and Treatment of Cancer-Related Infections nccn Guidelines Index Infections Table of Contents DiscussionClinical Trials: nccn believes that the best management for any cancer patient is in a Clinical trial. Participation in Clinical trials is especially encouraged. To find Clinical trials online at nccn Member Institutions, click Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

7 See nccn Categories of Evidence and nccn Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the nccn Guidelines is expected to use independent medical judgment in the context of individual Clinical circumstances to determine any patient s care or treatment. The National Comprehensive Cancer Network ( nccn ) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way.

8 The nccn Guidelines are copyrighted by National Comprehensive Cancer Network . All rights reserved. The nccn Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of nccn . Guidelines Prevention and Treatment of Cancer-Related Infections Panel MembersSummary of the Guidelines UpdatesAntimicrobial Prophylaxis (INF-1)Antifungal Prophylaxis (INF-2)Prevention of Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) Reactivation or Disease (INF-3)Prevention of Cytomegalovirus (CMV) Reactivation or Disease (INF-4)Prevention of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV)Reactivation or Disease (INF-5)Antipneumocystis Prophylaxis (INF-6)

9 General Recommendations for Vaccination in Patients with Cancer (INF-7)Recommended Vaccination Schedule After Autologous Or Allogeneic HCT(INF-8)Initial Evaluation of Fever and Neutropenia (FEV-1)Initial Risk Assessment for Febrile Neutropenic Patients (FEV-2)Outpatient Therapy for Low-Risk Patients (FEV-3)Initial Empiric Therapy For Fever And Neutropenia (FEV-5)Site-Specific Evaluation and Therapy:Mouth/Mucosal Membrane, Esophagus, and Sinus/Nasal (FEV-6)Abdominal Pain, Perirectal Pain, Diarrhea, and Urinary Tract Symptoms (FEV-7)Lung Infiltrates (FEV-8)Cellulitis/Skin and Soft Tissue Infections, Vascular Access Devices, Vesicular Lesions, Disseminated Papules or Other Lesions, and Central Nervous System Symptoms (FEV-9)Principles of Daily Follow-Up (FEV-10)Follow-Up Therapy for Responding Disease (FEV-11)Antibacterial Agents Table (FEV-A)Antifungal Agents Table (FEV-B)Antiviral Agents Table (FEV-C)

10 Risk Assessment Resources (FEV-D)Version , 05/20/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The nccn Guidelines and this illustration may not be reproduced in any form without the express written permission of nccn .Printed by Brian Hill on 10/1/2016 3:49:18 PM. For personal use only. Not approved for distribution. Copyright 2016 National Comprehensive Cancer Network, Inc., All Rights : All recommendations are category 2A unless otherwise Trials: nccn believes that the best management of any cancer patient is in a Clinical trial.